Do analysts recommend TCRT or PLX?

Protalix BioTherapeutics has a consensus price target of $12.00, indicating a potential upside of 418.36%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Alaunos Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts recommend TCRT or YDES?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, TCRT or YDES?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alaunos Therapeutics N/A N/A -$4.18M -$1.91 N/A YD Bio N/A N/A N/A N/A N/A

Is TCRT or YDES more profitable?

YD Bio's return on equity of 0.00% beat Alaunos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alaunos Therapeutics N/A -192.66% -140.32% YD Bio N/A N/A N/A

Do analysts recommend TCRT or CRBP?

Corbus Pharmaceuticals has a consensus price target of $41.00, indicating a potential upside of 300.98%. Given Corbus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than Alaunos Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Corbus Pharmaceuticals 2 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.60

Which has better valuation & earnings, TCRT or CRBP?

Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alaunos Therapeutics N/A N/A -$4.18M -$1.91 N/A Corbus Pharmaceuticals N/A N/A -$78.54M -$6.19 N/A

Is TCRT or CRBP more profitable?

Corbus Pharmaceuticals' return on equity of -87.05% beat Alaunos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alaunos Therapeutics N/A -192.66% -140.32% Corbus Pharmaceuticals N/A -87.05% -74.22%

Do analysts prefer TCRT or ABOS?

Acumen Pharmaceuticals has a consensus price target of $8.00, suggesting a potential upside of 191.44%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Alaunos Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Acumen Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has preferable earnings and valuation, TCRT or ABOS?

Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alaunos Therapeutics N/A N/A -$4.18M -$1.91 N/A Acumen Pharmaceuticals N/A N/A -$121.33M -$1.63 N/A

Is TCRT or ABOS more profitable?

Acumen Pharmaceuticals' return on equity of -136.27% beat Alaunos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alaunos Therapeutics N/A -192.66% -140.32% Acumen Pharmaceuticals N/A -136.27% -81.64%

Do analysts prefer TCRT or CHRS?

Coherus Oncology has a consensus target price of $8.67, suggesting a potential upside of 544.84%. Given Coherus Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Coherus Oncology is more favorable than Alaunos Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Coherus Oncology 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75

Alaunos Therapeutics (TCRT) Competitors

$1.87 -0.04 (-2.09%)

As of 03:10 PM Eastern

Compare

TCRT vs. PLX, YDES, CRBP, ABOS, and CHRS

Should you buy Alaunos Therapeutics stock or one of its competitors? Alaunos Therapeutics's main competitors and comparable companies include Protalix BioTherapeutics (PLX), YD Bio (YDES), Corbus Pharmaceuticals (CRBP), Acumen Pharmaceuticals (ABOS), and Coherus Oncology (CHRS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Alaunos Therapeutics compare to Protalix BioTherapeutics?

Alaunos Therapeutics (NASDAQ:TCRT) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by company insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Protalix BioTherapeutics had 4 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 6 mentions for Protalix BioTherapeutics and 2 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.47 beat Protalix BioTherapeutics' score of 0.09 indicating that Alaunos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Alaunos Therapeutics	Positive
Protalix BioTherapeutics	Neutral

Protalix BioTherapeutics has higher revenue and earnings than Alaunos Therapeutics. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$1.91	N/A
Protalix BioTherapeutics	$80.62M	2.31	$8.31M	$0.23	10.07

Protalix BioTherapeutics has a consensus price target of $12.00, indicating a potential upside of 418.36%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Alaunos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Alaunos Therapeutics has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-192.66%	-140.32%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Alaunos Therapeutics has a beta of -1, suggesting that its share price is 200% less volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market.

Summary

Protalix BioTherapeutics beats Alaunos Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Alaunos Therapeutics compare to YD Bio?

Alaunos Therapeutics (NASDAQ:TCRT) and YD Bio (NASDAQ:YDES) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

YD Bio's return on equity of 0.00% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-192.66%	-140.32%
YD Bio	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, YD Bio had 1 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 3 mentions for YD Bio and 2 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.47 beat YD Bio's score of 0.39 indicating that Alaunos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Alaunos Therapeutics	Positive
YD Bio	Neutral

27.7% of Alaunos Therapeutics shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$1.91	N/A
YD Bio	N/A	N/A	N/A	N/A	N/A

Summary

Alaunos Therapeutics and YD Bio tied by winning 3 of the 6 factors compared between the two stocks.

How does Alaunos Therapeutics compare to Corbus Pharmaceuticals?

Alaunos Therapeutics (NASDAQ:TCRT) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$1.91	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$6.19	N/A

Corbus Pharmaceuticals has a consensus price target of $41.00, indicating a potential upside of 300.98%. Given Corbus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than Alaunos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60

Corbus Pharmaceuticals' return on equity of -87.05% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-192.66%	-140.32%
Corbus Pharmaceuticals	N/A	-87.05%	-74.22%

27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 16.1% of Alaunos Therapeutics shares are owned by insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Corbus Pharmaceuticals had 4 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 6 mentions for Corbus Pharmaceuticals and 2 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.47 beat Corbus Pharmaceuticals' score of 0.28 indicating that Alaunos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Alaunos Therapeutics	Positive
Corbus Pharmaceuticals	Neutral

Alaunos Therapeutics has a beta of -1, suggesting that its share price is 200% less volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.59, suggesting that its share price is 159% more volatile than the broader market.

Summary

Corbus Pharmaceuticals beats Alaunos Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Alaunos Therapeutics compare to Acumen Pharmaceuticals?

Alaunos Therapeutics (NASDAQ:TCRT) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$1.91	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.63	N/A

Acumen Pharmaceuticals has a consensus price target of $8.00, suggesting a potential upside of 191.44%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Alaunos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Alaunos Therapeutics has a beta of -1, indicating that its stock price is 200% less volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market.

27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by company insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Acumen Pharmaceuticals' return on equity of -136.27% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-192.66%	-140.32%
Acumen Pharmaceuticals	N/A	-136.27%	-81.64%

In the previous week, Acumen Pharmaceuticals had 5 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 7 mentions for Acumen Pharmaceuticals and 2 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.47 beat Acumen Pharmaceuticals' score of 0.22 indicating that Alaunos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Alaunos Therapeutics	Positive
Acumen Pharmaceuticals	Neutral

Summary

Acumen Pharmaceuticals beats Alaunos Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Alaunos Therapeutics compare to Coherus Oncology?

Alaunos Therapeutics (NASDAQ:TCRT) and Coherus Oncology (NASDAQ:CHRS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

Alaunos Therapeutics has a beta of -1, suggesting that its share price is 200% less volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

Alaunos Therapeutics has a net margin of 0.00% compared to Coherus Oncology's net margin of -259.41%. Alaunos Therapeutics' return on equity of -192.66% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-192.66%	-140.32%
Coherus Oncology	-259.41%	-222.75%	-52.11%

In the previous week, Coherus Oncology had 13 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 15 mentions for Coherus Oncology and 2 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.47 beat Coherus Oncology's score of -0.09 indicating that Alaunos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Alaunos Therapeutics	Positive
Coherus Oncology	Neutral

27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 16.1% of Alaunos Therapeutics shares are owned by insiders. Comparatively, 7.2% of Coherus Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Coherus Oncology has higher revenue and earnings than Alaunos Therapeutics. Coherus Oncology is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$1.91	N/A
Coherus Oncology	$42.17M	4.92	$168.02M	-$1.03	N/A

Coherus Oncology has a consensus target price of $8.67, suggesting a potential upside of 544.84%. Given Coherus Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Coherus Oncology is more favorable than Alaunos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Coherus Oncology beats Alaunos Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Alaunos Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TCRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TCRT vs. The Competition

Export

Metric	Alaunos Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$45.67M	$3.84B	$7.10B	$12.84B
Dividend Yield	N/A	3.69%	2.56%	10.63%
P/E Ratio	-0.98	11.85	270.38	24.93
Price / Sales	N/A	1,241.94	578.10	73.31
Price / Cash	N/A	45.11	28.87	38.47
Price / Book	2.01	17.74	11.28	6.46
Net Income	-$4.18M	-$13.17M	$3.45B	$347.47M
7 Day Performance	-4.59%	1.20%	1.00%	0.36%
1 Month Performance	-8.78%	2.97%	2.45%	1.67%
1 Year Performance	-19.74%	54.77%	62.24%	19.30%

Alaunos Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TCRT Alaunos Therapeutics	1.2832 of 5 stars	$1.87 -2.1%	N/A	-15.1%	$45.67M	N/A	N/A	40	Positive News Earnings Report
PLX Protalix BioTherapeutics	2.66 of 5 stars	$2.36 -9.9%	$12.00 +408.5%	+54.7%	$190.15M	$76.38M	N/A	200	Positive News High Trading Volume
YDES YD Bio	N/A	$2.51 -3.5%	N/A	N/A	$184.05M	N/A	N/A	N/A	Gap Up
CRBP Corbus Pharmaceuticals	2.7776 of 5 stars	$10.08 +3.3%	$41.00 +306.7%	+13.4%	$182.23M	N/A	N/A	40	Gap Up High Trading Volume
ABOS Acumen Pharmaceuticals	2.0051 of 5 stars	$2.55 +1.6%	$8.00 +213.7%	+87.3%	$181.29M	N/A	N/A	20	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TCRT) was last updated on 8/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alaunos Therapeutics (TCRT) Competitors

TCRT vs. PLX, YDES, CRBP, ABOS, and CHRS

How does Alaunos Therapeutics compare to Protalix BioTherapeutics?

Summary

How does Alaunos Therapeutics compare to YD Bio?

Summary

How does Alaunos Therapeutics compare to Corbus Pharmaceuticals?

Summary

How does Alaunos Therapeutics compare to Acumen Pharmaceuticals?

Summary

How does Alaunos Therapeutics compare to Coherus Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRT vs. The Competition

Alaunos Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alaunos Therapeutics (TCRT) Competitors

TCRT vs. PLX, YDES, CRBP, ABOS, and CHRS

How does Alaunos Therapeutics compare to Protalix BioTherapeutics?

Do institutionals & insiders believe in TCRT or PLX?

Does the media refer more to TCRT or PLX?

Which has preferable valuation and earnings, TCRT or PLX?

Do analysts recommend TCRT or PLX?

Is TCRT or PLX more profitable?

Which has more risk and volatility, TCRT or PLX?

Summary

How does Alaunos Therapeutics compare to YD Bio?

Is TCRT or YDES more profitable?

Do analysts recommend TCRT or YDES?

Does the media favor TCRT or YDES?

Do insiders & institutionals believe in TCRT or YDES?

Which has stronger earnings & valuation, TCRT or YDES?

Summary

How does Alaunos Therapeutics compare to Corbus Pharmaceuticals?

Which has better valuation & earnings, TCRT or CRBP?

Do analysts recommend TCRT or CRBP?

Is TCRT or CRBP more profitable?

Do insiders and institutionals believe in TCRT or CRBP?

Does the media refer more to TCRT or CRBP?

Which has more volatility & risk, TCRT or CRBP?

Summary

How does Alaunos Therapeutics compare to Acumen Pharmaceuticals?

Which has preferable earnings and valuation, TCRT or ABOS?

Do analysts prefer TCRT or ABOS?

Which has more risk and volatility, TCRT or ABOS?

Do insiders & institutionals have more ownership in TCRT or ABOS?

Is TCRT or ABOS more profitable?

Does the media refer more to TCRT or ABOS?

Summary

How does Alaunos Therapeutics compare to Coherus Oncology?

Which has more volatility & risk, TCRT or CHRS?

Is TCRT or CHRS more profitable?

Does the media refer more to TCRT or CHRS?

Do institutionals & insiders have more ownership in TCRT or CHRS?

Which has higher valuation & earnings, TCRT or CHRS?

Do analysts prefer TCRT or CHRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRT vs. The Competition

Alaunos Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools